|
Amur Minerals Corp on Wednesday said its shareholders have approved multiple changes including its planned acquisition of Extruded Pharmaceuticals Ltd. The British Virgin Islands-registered cash shell, formerly a Russia-focused nickel copper sulphide exploration company, said all resolutions were passed at its annual general meeting and GM held on Wednesday morning. Amur Minerals said that, as a result, the proposals will become unconditional in all aspects. These include Amur’s acquisition of Extruded Pharmaceuticals for £5.5 million, through the issue of 23.9 million new shares, and Amur’s planned name change to CRISM Therapeutics Corp. Additionally, Amur Minerals shareholders endorsed the resignation of its minerals and geology-focused board: Non-Executive Chair Robert Schafer, Chief Executive Officer Robin Young, and Non-Executive Directors Thomas Bowens and Paul Gazzard. In their place, Amur Minerals said Nermeen Varawalla will be appointed independent non-executive chair, joined by Andrew Webb as CEO. Additionally, Christopher McConville will become chief scientific officer and Gerald Beaney an independent non-executive director. Amur Minerals said voters also approved a share consolidation, whereby investors will receive one new share for every 160 existing shares held. Amur Minerals shares are suspended from trading in London. They were last priced at 0.09 pence back in September last year. Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
